The Italian neuromodulation startup Newronika has secured a European approval for its closed-loop, adaptive implant for ...

Newronika has secured CE Mark approval for its AlphaDBS device aimed at the treatment of Parkinson's disease (PD), in Europe.

Newronika, a leader in neuromodulation and adaptive deep brain stimulation (DBS) technology, announced today that it has ...

Newronika announced today that it received CE mark approval for its AlphaDBS device for treating Parkinson's disease.

"I wanted to create a new barrier gate to keep unauthorized boaters from accessing a boat slip," said an inventor, from Mission Viejo¸ Calif., "so I invented the DOCK BLOCKER. My design ensures the ...

Following 12 months in Abbott’s trial, the patients involved will have their DBS system turned on and be observed for two years, irrespective of whether they were in the treatment or control arm.

Approximately 500,000 Americans are diagnosed with Parkinson’s disease, according to the National Institutes of Neurological Disorders and Stroke. Image credit: Kateryna Kon via Shutterstock.

MILAN, Feb. 13, 2025 /PRNewswire/ -- Newronika, a global leader in advanced deep brain stimulation, is pleased to announce the successful closing of its €13.6 million Series B funding round.